{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:09:14Z","timestamp":1789985354011,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.berh.2012.07.002","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T16:19:31Z","timestamp":1349453971000},"page":"477-487","source":"Crossref","is-referenced-by-count":47,"title":["Biological treatment in adult-onset Still's disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Jacques","family":"Pouchot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Beno\u00eet","family":"Arlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2012.07.002_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still's disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib2","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2012.07.002_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Practice Research and Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","article-title":"Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan","volume":"7","author":"Wakai","year":"1997","journal-title":"Journal of Epidemiology"},{"key":"10.1016\/j.berh.2012.07.002_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0950-3579(05)80283-3","article-title":"Adult-onset Still's disease","volume":"5","author":"van de Putte","year":"1991","journal-title":"Bailliere's Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France","volume":"54","author":"Magadur-Joly","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jbspin.2006.07.003","article-title":"How can we improve the management of adult-onset Still's disease?","volume":"74","author":"Pouchot","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2012.07.002_bib9","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib10","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ncprheum0510","article-title":"Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?","volume":"3","author":"Efthimiou","year":"2007","journal-title":"Nature Clinical Practice Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.revmed.2004.11.021","article-title":"Current concepts on the physiopathology of adult-onset Still's disease","volume":"26","author":"Arlet","year":"2005","journal-title":"Revue de M\u00e9decine Interne"},{"key":"10.1016\/j.berh.2012.07.002_bib13","first-page":"396","article-title":"Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease","volume":"25","author":"Hoshino","year":"1998","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2012.07.002_bib15","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib17","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease","volume":"31","author":"Chen","year":"2004","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib18","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still's disease","volume":"30","author":"Choi","year":"2003","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body","volume":"27","author":"Martinon","year":"2009","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.berh.2012.07.002_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jbspin.2008.05.009","article-title":"Is Still's disease an autoinflammatory syndrome?","volume":"76","author":"Hayem","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2012.07.002_bib21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0140-6736(05)79252-7","article-title":"Tnfalpha and response of treatment-resistant adult-onset Still's disease to thalidomide","volume":"352","author":"Stambe","year":"1998","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.berh.2012.07.002_bib22","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60","author":"Kraetsch","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib23","first-page":"329","article-title":"Infliximab in the treatment of adult Still's disease refractory to conventional therapy","volume":"19","author":"Cavagna","year":"2001","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10067-003-0775-5","article-title":"Successful treatment of refractory adult-onset Still's disease with infliximab. A\u00a0prospective, non-comparative series of four patients","volume":"23","author":"Kokkinos","year":"2004","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib25","first-page":"113","article-title":"A case of adult onset Still's disease treated with infliximab","volume":"20","author":"Caramaschi","year":"2002","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10067-003-0744-z","article-title":"Infliximab in a case of early adult-onset Still's disease","volume":"22","author":"Olivieri","year":"2003","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib28","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis b virus treated for an adult onset Still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.61.9.859-a","article-title":"Adult onset Still's disease: response to Enbrel","volume":"61","author":"Asherson","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10067-004-1064-7","article-title":"Prolonged remission in adult-onset Still's disease with etanercept","volume":"25","author":"Kumari","year":"2006","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.amjmed.2003.04.001","article-title":"Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease","volume":"115","author":"Serratrice","year":"2003","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.berh.2012.07.002_bib34","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2012.07.002_bib35","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2012.07.002_bib36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/rheumatology\/kem066","article-title":"Adult-onset Still\u2019s disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept","volume":"46","author":"Kuek","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2012.07.002_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00296-008-0619-3","article-title":"Etanercept as a rescue agent in patient with adult onset Still\u2019s disease complicated with congestive heart failure","volume":"29","author":"Yang","year":"2008","journal-title":"Rheumatology International"},{"key":"10.1016\/j.berh.2012.07.002_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","article-title":"A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis","volume":"25","author":"Pay","year":"2006","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group","volume":"342","author":"Lovell","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2012.07.002_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00296-009-1204-0","article-title":"A rare trigger for macrophage activation syndrome","volume":"31","author":"Agarwal","year":"2011","journal-title":"Rheumatology International"},{"key":"10.1016\/j.berh.2012.07.002_bib41","first-page":"733","article-title":"Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report","volume":"23","author":"Benucci","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1055\/s-2004-826865","article-title":"Longterm outcome of TNF blockade in adult-onset Still's disease","volume":"129","author":"Dechant","year":"2004","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.berh.2012.07.002_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.20001","article-title":"A 21-year-old man with Still's disease with fever, rash, and pancytopenia","volume":"62","author":"Mehta","year":"2010","journal-title":"Arthritis Care and Research (Hoboken)"},{"key":"10.1016\/j.berh.2012.07.002_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-011-1735-0","article-title":"Is anti-TNF switching in refractory Still's disease safe and effective?","volume":"30","author":"Aikawa","year":"2011","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib45","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib46","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Medical Weekly"},{"key":"10.1016\/j.berh.2012.07.002_bib47","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1136\/ard.2008.105833","article-title":"A patient's wish: anakinra in pregnancy","volume":"68","author":"Berger","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","article-title":"Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial","volume":"66","author":"Kalliolias","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature","volume":"37","author":"Kotter","year":"2007","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib51","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2010.129403","article-title":"Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade","volume":"70","author":"Rech","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Puechal","year":"2011","journal-title":"Arthritis Care and Research (Hoboken)"},{"key":"10.1016\/j.berh.2012.07.002_bib53","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/archderm.142.12.1591","article-title":"Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1\/NALP3 mutations","volume":"142","author":"Leslie","year":"2006","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.berh.2012.07.002_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RHU.0b013e318188b8d8","article-title":"Efficacy of anakinra in a case of refractory Still disease","volume":"14","author":"Debiais","year":"2008","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra","volume":"64","author":"Vasques Godinho","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib56","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/art.24826","article-title":"Thrombotic microangiopathy and Purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor?","volume":"61","author":"El Karoui","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib57","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib58","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib61","first-page":"758","article-title":"Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report","volume":"25","author":"Guignard","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10165-009-0254-1","article-title":"Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease","volume":"20","author":"Tamaki","year":"2010","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib63","first-page":"939","article-title":"Effective treatment of steroid refractory adult-onset Still's disease with anakinra","volume":"35","author":"Maier","year":"2008","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib64","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1756-185X.2010.01474.x","article-title":"A case of refractory adult-onset Still's disease treated with anakinra","volume":"13","author":"Lahiri","year":"2010","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib65","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2012.07.002_bib66","unstructured":"Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Seminars in Arthritis and Rheumatism: in press."},{"key":"10.1016\/j.berh.2012.07.002_bib67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib68","unstructured":"Petryna O, Cush JJ, Efthimiou P. IL-1 trap rilonacept in refractory adult onset Still's disease. Annals of the Rheumatic Diseases: in press."},{"key":"10.1016\/j.berh.2012.07.002_bib69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semarthrit.2006.07.001","article-title":"Pathogenesis and management of adult-onset Still's disease","volume":"36","author":"Efthimiou","year":"2006","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib70","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.10620","article-title":"Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease","volume":"46","author":"Iwamoto","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10067-009-1097-z","article-title":"Glucocorticoid and cyclosporine refractory adult onset Still\u2019s disease successfully treated with tocilizumab","volume":"28","author":"Matsumoto","year":"2009","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still's disease","volume":"68","author":"De Bandt","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.07.002_bib73","unstructured":"Naniwa T, Ito R, Watanabe M, et\u00a0al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clinical Rheumatology: in press."},{"key":"10.1016\/j.berh.2012.07.002_bib74","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-010-1418-2","article-title":"Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab","volume":"29","author":"Sumida","year":"2010","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib75","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00296-010-1631-y","article-title":"Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature","volume":"31","author":"Thonhofer","year":"2011","journal-title":"Rheumatology International"},{"key":"10.1016\/j.berh.2012.07.002_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10165-008-0116-2","article-title":"A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years","volume":"19","author":"Nakahara","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib77","first-page":"141","article-title":"Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)","volume":"28","author":"Yoshimura","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib78","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10067-010-1553-9","article-title":"A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature","volume":"29","author":"Perdan-Pirkmajer","year":"2010","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10165-010-0365-8","article-title":"Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis","volume":"21","author":"Kishida","year":"2011","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib80","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10165-010-0348-9","article-title":"Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.semarthrit.2010.05.003","article-title":"Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis \u2013 efficacy of interleukin-6 blockade and review of the literature","volume":"40","author":"Sabnis","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2012.07.002_bib82","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.lpm.2011.03.012","article-title":"Antagonists of interleukin-6 (tocilizumab), in adult refractory Still disease","volume":"40","author":"Sekkach","year":"2011","journal-title":"La\u00a0Presse M\u00e9dicale"},{"key":"10.1016\/j.berh.2012.07.002_bib83","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2169\/internalmedicine.50.4771","article-title":"Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease","volume":"50","author":"Yoshida","year":"2011","journal-title":"Internal Medicine"},{"key":"10.1016\/j.berh.2012.07.002_bib84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-011-1917-9","article-title":"Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review","volume":"31","author":"Sakai","year":"2012","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib85","unstructured":"Suematsu R, Ohta A, Matsuura E, et\u00a0al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Modern Rheumatology: in press."},{"key":"10.1016\/j.berh.2012.07.002_bib86","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2012.07.002_bib87","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0248-8663(96)80703-X","article-title":"Treatment of Still disease in adults with intravenous immunoglobulins","volume":"16","author":"Permal","year":"1995","journal-title":"Revue de M\u00e9decine Interne"},{"key":"10.1016\/j.berh.2012.07.002_bib88","first-page":"295","article-title":"Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs","volume":"16","author":"Vignes","year":"1998","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/rheumatology\/keh172","article-title":"Adult onset Still\u2019s disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil","volume":"43","author":"Bennett","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 15","key":"10.1016\/j.berh.2012.07.002_bib90","first-page":"S85","article-title":"High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience","volume":"14","author":"De Vita","year":"1996","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib91","first-page":"253","article-title":"Hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura (HUS\/TTP) complicating adult Still\u2019s disease: remission induced with intravenous immunoglobulin g","volume":"10","author":"Diamond","year":"1997","journal-title":"Journal of Nephrology"},{"key":"10.1016\/j.berh.2012.07.002_bib92","first-page":"1058","article-title":"Adult Still's disease: a multicenter survey of Japanese patients","volume":"17","author":"Ohta","year":"1990","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib93","first-page":"2067","article-title":"Intravenous immunoglobulin in the treatment of refractory adult Still's disease","volume":"26","author":"Mahmud","year":"1999","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib94","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/rheumatology\/38.10.1024","article-title":"Intravenous immunoglobulins for adult Still's disease and pregnancy","volume":"38","author":"Liozon","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2012.07.002_bib95","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(96)90521-8","article-title":"Treatment of adult Still's disease with intravenous immunoglobulin","volume":"347","author":"Kulke","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2012.07.002_bib96","first-page":"797","article-title":"Intravenous immunoglobulins in Still's disease: still controversial, still unproven","volume":"23","author":"Prieur","year":"1996","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","article-title":"Refractory adult-onset still disease successfully treated with abatacept","volume":"17","author":"Ostrowski","year":"2011","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib98","first-page":"265","article-title":"Efficacy of abatacept in a refractory case of adult-onset Still's disease","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.07.002_bib99","first-page":"758","article-title":"Adult Still's disease. Part II. Management, outcome, and prognostic factors","volume":"62","author":"Masson","year":"1995","journal-title":"Revue du Rhumatisme (English Edition)"},{"key":"10.1016\/j.berh.2012.07.002_bib100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-010-1459-6","article-title":"May anakinra be used earlier in adult onset Still disease?","volume":"29","author":"Moulis","year":"2010","journal-title":"Clinical Rheumatology"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694212000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694212000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:45:45Z","timestamp":1744245945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694212000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1521694212000654"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2012.07.002","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}